Prix Galien USA 2020

Nominees for Best Pharma

The onset of COVID-19 has upended the business of health care, including the $1 trillion global market for prescription pharmaceuticals. Reliance on the R&D industry to develop a vaccine to defeat the contagion has introduced new obligations and raised the stakes on drug makers reputation and responsibility to society.

On the positive side, it has created new incentives for collaborative partnerships, particularly with regulators. The down side is the slower pace of new market launches in other areas of unmet patient need, a decline in elective procedures requiring drugs, and more distractions among providers, payers and key institutional clients who remain focused on managing their own pandemic-related exposures. The fact is there is no real consensus on how the pandemic will reshape the future of health provision, financing, government regulation and patient expectations. Learnings from the pandemic crisis may lead to new entrants to the medicines market as well as a greater role for public intervention in regulating the distribution and cost of care. Those who can leverage productivity gains from advanced information technologies like AI and digital medicine, including many from outside health care itself, have the potential to disrupt big pharma’s pre-pandemic business model for good. To mark the Prix Galien USA’s upcoming October 26 “Week of Discovery and Celebration on the Frontiers of Medical Innovation,” distinguished members of the USA Galien Awards Committee will chair three webinars highlighting each of the 26 nominee products they have selected in the best Pharmaceuticals category.

These virtual expert panelist exchanges will offer the opportunity for webinar participants to review the current state of innovation in biopharma, covering key aspects of clinical progress and differentiation; the ways that patient care is now being conducted outside the traditional delivery setting; and the next wave of promising digital and gene-based drug therapies, including their transformative – and potentially disruptive – effect on health care productivity and outcomes worldwide.

Best_Pharma

Best Pharmaceutical Product Nominees 2020

ProductManufacturerTherapeutic Area &
Indication
RINVOQ®AbbVie Inc.JAK (janus kinase) inhibitor that blocks inflammation of moderate to severe
rheumatoid arthritis (RA) in patients who don’t benefit from existing treatments
REYVOW (lasmiditan)Eli Lilly and CompanyA serotonin (5-HT) 1F receptor agonist indicated for the acute treatment of migraine with or without aura in adults
Olumiant®Eli Lilly and CompanyJAK inhibitor for treatment of Rheumatoid Arthritis in patients
who fail to benefit from existing TNF alpha inhibitor therapies
Entresto®Novartis PharmaceuticalsReduce hospitalizations and deaths in adults with chronic heart failure
through improvement in the heart’s ability to pump blood to the body
VYNDAQUEL®PfizerFor cardiomyopathy associated with transthyretin-mediated amyloidosis
(ATTR-CM) to reduce cardiovascular mortality and related hospitalizations
Adhansia XRPurdue PharmaCentral nervous system stimulant to treat attention deficit hyperactivity
disorder (ADHD) in people age six and older
YUPELRITheravance, IncAnticholinergic to treat chronic obstructive pulmonary disease (COPD),
including emphysema and chronic bronchitis
LutatheraAdvanced Accelerator Applications USARadioactive isotope treatment for cancerous neuroendocrine
tumors affecting the pancreas or gastrointestinal tract
DarolutamideBayer U.S., LLCFor patients with non-metastatic castration-resistant prostate cancer
LarotrectinibBayer U.S., LLC“Tumor agnostic” treatment based on a common biomarker across
different types of cancers and indicated for patients with solid
tumors characterized by a neurotrophic receptor kinase (NTRK)
gene fusion mutation and whose cancer has metastasized
RozlytrekGenentech/RocheFirst “tumor agnostic” treatment with biomarkers to specifically
target ROS-1 positive metastatic non-small cell lung cancer
(NSCLC) as well as other NTRK gene fusion positive solid tumors
Erleada (apalutimide)Janssen PharmaceuticalsNon-steroidal anti-androgen treatment for prostate cancer in
conjunction with castration in cases that are non-metastatic and
resistant to castration
BALVERSAJohnson & JohnsonKinase inhibitor to treat adults with advanced or metastatic
urothelial cancers that are susceptible to FGFR2 or FGFR3
mutations or have proven resistant to chemotherapy
ERLEADA®Johnson & JohnsonKinase inhibitor to treat adults with advanced or metastatic
urothelial cancers that are susceptible to FGFR2 or FGFR3
mutations or have proven resistant to chemotherapy
PIQRAY®NovartisTreatment of advanced or metastatic breast cancer with PIK3CA gene mutation
LorbrenaPfizerFor patients with anaplastic lymphoma kinase (ALK) positive
metastatic non-small cell lung cancer (NSCLC) in cases where
previous ALK inhibitors have failed
XOSPATA®Astellas PharmaTyrosine kinase inhibitor for adults with relapsed or refractory acute
myeloid leukemia (AML) with the tyrosine kinase-3 gene mutation
XPOVIOKaryopharm TherapeuticsTreatment of relapsed/refractory (RR) multiple myeloma and
RR diffuse large B-cell lymphoma
ASPARLAS™Servier PharmaceuticalsComponent therapy of a multi-agent chemotherapy regimen for
treatment of acute lymphoblastic leukemia (ALL) in patients 21
years of age or younger
Adakveo®NovartisTreatment to lower frequency of recurrent vaso-occlusive crises associated
with severe vascular system pain for conditions like sickle cell anemia
Epidiolex®Sam Brown IncReduction of seizures associated with Leno-Gastaut Syndrome (LGS), Dravet
Syndrome and Tuberous Sclerosis Complex (TSC) in adults and infant children
Gamifant®Sobi, Inc.First treatment for infants/adults with primary haemophagocytic
lymphohistiocytosis (HLH), an ultra-rare immune disorder that leads to severe
inflammation, infections, bleeding, organ failures and early death.
MoxidectinMedicines Development for Global Health and the World Health Organization (WHO)New treatment for onchocerciasis (river blindness) demonstrating superiority over ivermectin, the current standard of care against this major neglected infectious disease prevalent in developing countries.
RECARBRIO™Merck & Co., IncCombination anti-bacterial for adults with complicated urinary tract infections and complicated intra-abdominal infections
Annovera (segesterone acetate and ethinyl estradiol vaginal system)Population Council Inc.Novel hormonal contraceptive vaginal ring that prevents ovulation and pregnancy over a full-year cycle of use
Tpoxx (tecovirimat)SIGA Technologies Inc.First drug with an indication for treatment of smallpox in humans in the
event of its use as a bioweapon and public health emergency
Pretomanid (with bedaquiline and linezolid)TB AllianceA nitroimidazole drug, one of a class of novel anti-bacterials and approved as a combination with two other drugs for use in patients with highly
drug-resistant pulmonary tuberculosis (TB).